Morgans Analyst Iain Wilkie talks to CEO of ASX listed regenerative medicine and stem-cell player Regeneus (ASX:RGS) on what the company does and a number of potential catalysts which lie ahead.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
